ORCID as entered in ROS

Select Publications
2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 42, pp. 4 - 4, presented at American-Society-of-Clinical-Oncology: Genitourinary Cancers Symposium (ASCO GU), CA, San Francisco, 25 January 2024 - 27 January 2024, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.4
,2022, 'Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11570
,2021, 'A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: The VERTU study', in Neuro Oncology, Vol. 23, pp. 1736 - 1749, http://dx.doi.org/10.1093/neuonc/noab111
,2019, 'A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 37, presented at 55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2011
,